For instance, in urothelial cancer, combining Transforming Growth Factor β (TGF-β) blockade with ICIs therapy has been shown to promote T cell infiltration into the tumor core and elicit strong anti-tumor immune responses (44). This evidence concerns the gene TGFB1 and neoplasm.